医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promega Maxwell RNA Extraction System Authorized for Use in CDC COVID-19 Emergency Use Authorization (EUA) Diagnostic Panel

2020年07月16日 PM10:00
このエントリーをはてなブックマークに追加


 

MADISON, Wis.

Promega Corporation’s Maxwell® RSC 48 Instrument and Maxwell® RSC Viral Total Nucleic Acid Purification Kit (Maxwell Extraction System) are now in the Centers for Disease Control and Prevention’s (CDC) COVID-19 diagnostic protocol for emergency use. In a letter dated July 13, 2020, the U.S. Food and Drug Administration (FDA) authorized an amendment to the CDC’s 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel stating the Promega Maxwell Extraction System is an authorized solution for laboratories that use the testing protocol.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005217/en/

The Promega Maxwell® RSC 48 Instrument and Maxwell® RSC Viral Total Nucleic Acid Purification Kit are now authorized RNA extraction options in the Centers for Disease Control and Prevention’s (CDC) COVID-19 diagnostic protocol for emergency use. (Photo: Business Wire)

The Promega Maxwell® RSC 48 Instrument and Maxwell® RSC Viral Total Nucleic Acid Purification Kit are now authorized RNA extraction options in the Centers for Disease Control and Prevention’s (CDC) COVID-19 diagnostic protocol for emergency use. (Photo: Business Wire)

“This announcement further validates why the Maxwell Extraction System is in such high demand by clinical testing labs seeking consistent and reliable benchtop automation,” says Heather Tomlinson, Promega Director of Clinical Diagnostics. “We are happy our Maxwell customers that use the CDC’s protocol now have the flexibility of one more authorized RNA extraction option in the SARS-CoV-2 testing process.”

The Maxwell RSC 48 Instrument and Maxwell RSC Viral Total Nucleic Acid Purification Kit work together as an automated sample preparation solution that extracts RNA and DNA from viral samples. The small, benchtop Maxwell instrument is capable of processing and purifying approximately 400 samples in a typical 8-hour shift.

In addition to the CDC’s EUA assay, many other assay developers have incorporated the Maxwell instrument and reagents into their own COVID-19 EUA assays. Some developers who are targeting extremely high-throughput testing have leveraged Promega Maxwell HT reagents that are used with high-throughput robotics to automate the extraction of thousands of samples per day.

Promega supplies automation, sample extraction and diagnostic reagents to customers around the world. The company’s reagents are currently incorporated in 29 COVID-19 diagnostic tests produced by other global diagnostic manufacturers. The Promega GoTaq® Probe 1-Step RT-qPCR System is also authorized for use in the CDC’s 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel for emergency use.

For specific product details about the Promega Maxwell RNA Extraction System visit: www.promega.com/Maxwell48

To learn more about Promega SARS-CoV-2 products and Promega technical support visit: www.promega.com/covid19

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. Our product portfolio of over 4,000 products support a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. For over 40 years these tools and technologies have grown in their application and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information, visit www.promega.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005217/en/

CONTACT

Contact: Penny Patterson

VP, Communications

Promega Corporation

Phone: (608) 274-4330

E-mail: penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy
  •  CG Creative Studios Wins Gold Stevie® Award in 2020 Asia-Pacific Stevie Awards
  • Largest Global Forensic DNA Meeting, International Symposium on Human Identification (ISHI), Going Virtual for 2020
  • Vyripharm International, Inc. and the National Yang-Ming University Signed a MOU to Develop VYR-206 as a Novel Diagnostic Approach for Neurological Disorders Outcomes Following Treatments
  • 患者安全運動財団、米国麻酔学会、ザ・リープフロッグ・グループ、医療の質に関する国際学会が世界患者安全の日キャンペーンの#UniteForSafeCareに向け力を合せる